Daily Research Report



T2

59112

53658

Dt.: 29th July. 2025

INDEX	NIFTY	BANKNIFTY	USDINR
Outlook	Neutral	Neutral	Neutral

INSTITUTIONAL TRADING ACTIVITY IN CRS.

Category	Buy Value	Sell Value	Net Value
FII	9,993.78	16,076.25	-6,082.47
DII	15,799.53	9,034.98	+6,764.55


TRADE S	STATISTICS	FOR 28/	07/2025
---------	------------	---------	---------

Instrument	No. of Contracts	Turnover (Cr.)	Put Call Ratio
Index Fut.	155844	29685.69	
Stock Fut.	1816967	122311.1	
Index Opt.	65567568	12402296	0.58
Stock Opt.	8676413	615433.4	
F&O Total	76216792	13169726	

Nifty Action: 28/07/2025



PIVOT TABLE					
	R2	R1	PIVOT	S1	S2
NIFTY	25264	24958	24680	24321	24004
BANKNIFTY	57887	57001	56060	54714	54171





Nifty extended its decline for the third consecutive session, closing below the 24700 options base and breaching the support of its declining channel pattern, indicating vulnerability to a sharper fall toward 24560 and potentially 24300 if weakness persists in the final leg of the July series. Technical indicators maintain a bearish bias, with ADX above 29 signalling strong downward momentum and RSI below 37 reflecting weakness, though oversold conditions are apparent. The OI-PCR at 0.51 for Nifty and 0.60 for Bank Nifty suggests scope for a short-term rebound. Options data shows strong resistance at 25000 and immediate support at 24700, while India VIX below 12 keeps volatility subdued. A close above 25250 is crucial to end the consolidation phase, and a recovery above 25000 would preserve a rangebound structure; failure to regain this level could drag the index lower toward 24560 and 24300. Traders are advised to adopt a long-short strategy with strict risk management until a decisive breakout occurs.

Trade Scanner: ALKEM, BALKRISIND, DRREDDY, ICICIBANK, KALYANKJIL, LAURUSLABS, PAYTM, SBILIFE, SUNPHARMA, TORNTPHARM, ABB, HAVELLS, HINDALCO, IDFCFIRSTB, INDIGO, INDUSINDBK, IREDA, LODHA, PHOENIXLTD, PRESTIGE

RESEARCH DESK: Sacchitanand Uttekar - VP - Research (Derivatives & Technicals)

Disclaimer: Investments in securities market are subject to market risk, read all the related documents carefully before investing.

Disclaimer: This document is for private circulation and information of a private circulation and information of a private circulation and information of a private circulation of any offer to buy or sell the Equity derivatives mentioned herein. We and our affiliates group? companies, directors and employees, and directors and employees of our affiliates and group? companies, including persons involved in the preparation or issuance of this material may (a) have positions which might have conflicting interest with respect to any related information. The information contained hereby may have been taken from sources which we believe are reliable. We do not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinion expressed reflects judgments at this date and are subject to change without notice. Risk of loss in Equity derivatives trading can be substantial. Persons trading in Equity Derivatives should consider the suitability of trading based upon their resources, risk appetite and other relevant information, and understand that statements regarding future prospects may not be realized

